ESC & iPSC News
ESC & iPSC News is an online resource dedicated to the latest research in the fields of embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs).
α-Ketoglutarate Promotes Trophectoderm Induction and Maturation from Naive Human Embryonic Stem Cells
[Nature Cell Biology] Investigators uncovered that inducing naive hESCs towards the trophectoderm lineage resulted in considerable metabolic rewiring, characterized by α-ketoglutarate accumulation.
The Building Blocks of Embryo Models: Embryonic and Extraembryonic Stem Cells
[Cell Discovery] The authors summarize the characteristics of existing mouse and human embryonic and extraembryonic stem cells and review recent advancements in developing mouse and human embryo models
Chemical-Based Epigenetic Reprogramming to Advance Pluripotency and Totipotency
[Nature Chemical Biology] Over the past decade, a notable focus has been reshaping cellular pluripotency and totipotency using pure small-molecule systems.
Japan’s Big Bet on Stem-Cell Therapies Might Soon Pay off with Medical Breakthroughs
[Nature] iPSCs are being tested to treat blindness, paralysis, Parkinson’s disease and more. Approvals might be around the corner.
Single-Cell 5-Hydroxymethylcytosine Landscapes of Mouse Early Embryos at Single-Base Resolution
[Cell Reports] Investigators elucidated the dynamics of active DNA demethylation during mouse preimplantation development
Applied StemCell Announces Drug Master File Submission to the US FDA for their GMP-Grade iPSC Cell Line
[Applied StemCell, Inc.] Applied StemCell, Inc. announced that they have submitted a Type II Drug Master File to the US FDA for their ActiCellsâ„¢ GMP hiPSC line.
Cellino Announces Partnership with Karis Bio to Develop First Nebulaâ„¢-Powered Autologous iPSC Therapy for Cardiovascular Disease
[Cellino (BioSpace)] Cellino announced its expansion into the Asia-Pacific region through a strategic collaboration with Karis Bio, a leading South Korean cell therapy biotech. The partnership aims to industrialize the world’s first clinical-stage autologous iPSC-derived cell therapy for peripheral artery disease and coronary artery disease.
XellSmart’s Allogeneic iPSC-Derived Cell Therapies for Parkinson’s Disease and ALS Officially Approved by the US FDA for Phase I Clinical Trials
[XellSmart Biomedical (Suzhou) Co., Ltd] The US FDA officially approved the Investigational New Drug application submitted by XellSmart Biopharmaceutical (Suzhou) Co., Ltd. for its universal allogeneic off-the-shelf iPS-derived dopaminergic neural progenitor cell therapy for the treatment of Parkinson’s disease.
hPSC-Based Treatment of Retinal Diseases – Current Progress and Challenges
[Advanced Drug Delivery Reviews] Cell-based therapies using iPSCs or ESCs offer potential solutions for restoring damaged retinal cells. The authors summarize recent advances in retinal pigment epithelium and photoreceptor cells transplantation, highlighting the benefits of each approach.
Tracing Genomic Instability in Induced Mesenchymal Stromal Cell Manufacture: An Integration-Free Transfection Approach
[British Journal of Cancer] Scientists investigated the genomic changes occurring during the process of generating and passaging iPSCs and differentiating them into iPSC-derived mesenchymal stem cells (iMS), as well as the changes that occured during iMS cell passage.
EIF3D Safeguards the Homeostasis of Key Signaling Pathways in Human Primed Pluripotency
[Science Advances] Researchers showed that translational regulation by EIF3 subunit D (EIF3D) was critical for maintaining the identity of primed hPSCs.
The Regulatory Architecture of the Primed Pluripotent Cell State
[Nature Communications] Researchers presented an integrative systems biology approach to elucidate the network architecture of primed state pluripotency.
Since 2007, ESC & iPSC News has been providing updates on the top publications, reviews, and news in pluripotent stem cell research. Through our website, Twitter, and email newsletters, our editorial team is proud to help keep researchers and medical professionals up-to-date with the latest discoveries, jobs, and event postings in the pluripotent stem cell field.